The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study by Francesco Russo et al.
Russo et al. BMC Cancer 2013, 13:56
http://www.biomedcentral.com/1471-2407/13/56RESEARCH ARTICLE Open AccessThe effects of fluorouracil, epirubicin, and
cyclophosphamide (FEC60) on the intestinal
barrier function and gut peptides in breast cancer
patients: an observational study
Francesco Russo1†, Michele Linsalata1†, Caterina Clemente1, Benedetta D’Attoma1, Antonella Orlando1,
Giovanna Campanella2, Francesco Giotta3 and Giuseppe Riezzo4*Abstract
Background: Several GI peptides linked to intestinal barrier function could be involved in the modification of
intestinal permeability and the onset of diarrhea during adjuvant chemotherapy. The aim of the study was to
evaluate the circulating levels of zonulin, glucagon-like peptide-2 (GLP-2), epidermal growth factor (EGF) and
ghrelin and their relationship with intestinal permeability and chemotherapy induced diarrhea (CTD).
Methods: Sixty breast cancer patients undergoing an FEC60 regimen were enrolled, 37 patients completed the
study. CTD(+) patients were discriminated by appropriate questionnaire and criteria. During chemotherapy,
intestinal permeability was assessed by lactulose/mannitol urinary test on day 0 and day 14. Zonulin, GLP-2, EGF
and ghrelin circulating levels were evaluated by ELISA tests at five time-points (days 0, 3, 10, 14, and 21).
Results: During FEC60 administration, the lactulose/mannitol ratio was significantly higher on day 14 than at
baseline. Zonulin levels were not affected by chemotherapy, whereas GLP-2 and EGF levels decreased significantly.
GLP-2 levels on day 14 were significantly lower than those on day 0 and day 3, while EGF values were significantly
lower on day 10 than at the baseline. In contrast, the total concentrations of ghrelin increased significantly at day 3
compared to days 0 and 21, respectively. Ten patients (27%) suffered from diarrhea. On day 14 of chemotherapy, a
significant increase of the La/Ma ratio occurred in CTD(+) patients compared to CTD(−) patients. With regards to
circulating gut peptides, the AUCg of GLP-2 and ghrelin were significantly lower and higher in CTD(+) patients than
CTD(−) ones, respectively. Finally in CTD(+) patients a significant and inverse correlation between GLP-2 and La/Ma
ratio was found on day 14.
Conclusions: Breast cancer patients undergoing FEC60 showed alterations in the intestinal permeability, which was
associated with modifications in the levels of GLP-2, ghrelin and EGF. In CTD(+) patients, a different GI peptide
profile and increased intestinal permeability was found in comparison to CTD(−) patients. This evidence deserves
further studies for investigating the potentially different intestinal luminal and microbiota conditions.
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The complications of anti-cancer chemotherapy include
gastrointestinal (GI) mucositis, which represents injury
of the rest of the alimentary tract beyond oral mucositis.
This condition is most prominent in the small intestine,
but it also occurs in the esophagus, stomach, and large
intestine [1].
GI mucositis induced by chemotherapy is associated
with alterations of intestinal barrier function [2] due to
the potential damage induced by the anti-cancer drugs
on the epithelial cells of the intestinal mucosa. Cytotoxic
drugs impair the turn-over of intestinal epithelia and in-
duce flattening of the villi and an increased exposure of
luminal contents to crypts [3]. These alterations could
be involved in the frequent recurrence of GI symptoms,
such as abdominal pain and diarrhea, in patients under-
going chemotherapy [4].
At present lactulose/mannitol (La/Ma) double sugar
absorption test represents an appropriate, noninvasive
method for evaluation of intestinal permeability. Lactulose
is a disaccharide that reflects the permeability of large
molecules (0.93 nm), mannitol is a monosaccharide
that can be considered a marker of absorption of small
molecules (0.65 nm) [5]. An increased disaccharide/
monosaccharide ratio and decreased xylose absorption
have been described in experimental animal models [6]
and patients with GI cancer [7] treated with different
cytotoxic agents [8]. Notwithstanding, there is still
much to learn about the occurrence of chemotherapy-
induced alterations for extra-GI neoplasms [9] and in
particular with recent FEC60 regimen (fluorouracil,
epirubicin, and cyclophosphamide) [10]. Furthermore, the
mechanisms underlying these alterations in neoplastic
patients are not fully elucidated, since there is still
a lack of information concerning all of the players
actively implicated in the regulation of intestinal barrier
function.
Functionally, the intestinal barrier is a dynamic sys-
tem, promptly responding to different stimuli ranging
from the dietary state and inflammatory mediators to
neuronal or humoral signals. Among the latter, zonulin
is able to modulate the mucosal barrier by disassem-
bling the tight intercellular junctions that characterize
the early phase of inflammatory states [11]. This protein
appears to play a key role in the pathogenesis of
autoimmune diseases such as celiac disease and type-1
diabetes [12]. A tight control of the intestinal barrier is
also exerted by other peptides. The Glucagon-like
peptide-2 (GLP-2) is an intestinotrophic growth hormone
that promotes many aspects of intestinal function,
including rapid enhancements of mucosal growth [13]
and the intestinal barrier function by affecting both
paracellular and transcellular pathways [14]. It has been
shown that GLP-2 possesses anti-apoptotic effects onintestinal crypt cells that may be useful for the attenuation
of chemotherapy-induced intestinal mucositis [15]. Along
with GLP-2, the epidermal growth factor (EGF) may play
an active role against chemotherapy-induced damage of
the intestinal mucosa. This 53 amino acid peptide shows a
broad range of bioactivities on the intestinal epithelium,
including the stimulation of cellular proliferation, dif-
ferentiation, and intestinal maturation [16]. Previous
studies have shown that EGF administration exerts a
protective role against a variety of intestinal insults by
either reducing injury or accelerating repair [17].
Another important molecule in regulating the mechan-
isms of the intestinal barrier is ghrelin, a 28 amino acid
peptide mainly produced by a subset of GI enteroendocrine
cells. This peptide has also been involved in the control
of the mucosal barrier and is considered a potential
protective agent against chemotherapy complications.
In mice, ghrelin administration has been demonstrated
to prevent the doxorubicin-induced GI mucosal dam-
age [18].
The link between the modifications of circulating
levels of these peptides, intestinal permeability and GI
symptom profiles in extra-GI cancer patients who had
undergone a second generation chemotherapy have yet
to be investigated. Therefore, in the present study the
La/Ma permeability test was applied to evaluate the in-
testinal damage in breast cancer patients when receiving
the first cycle of FEC60 adjuvant chemotherapy. The
effects of these cytotoxic drugs on circulating levels of
zonulin, GLP-2, EGF and ghrelin were investigated.
Lastly, the intestinal permeability and the gut peptide
profile of patients who suffered from diarrhea during
chemotherapy were also analyzed in comparison to
those of patients without diarrhea.
Methods
Patients
This prospective observational study focused on con-
secutive patients with breast cancer who underwent
adjuvant chemotherapy. Patients were recruited from
the outpatients of the oncology D.H. of the National
Institute of Digestive Diseases, I.R.C.C.S. “Saverio de
Bellis” and the Medical Oncology Unit of the National
Cancer Institute I.R.C.C.S. “Giovanni Paolo II”. They
were screened by two investigators (G.R. and F.G.) and
recruited according to the inclusion criteria and their
willingness to participate. The study began in July 2010
and enrollment of patients ended in September 2011.
Sixty female patients were enrolled, and 37 subjects
(age 60.1±1.7 years) completed the prospective obser-
vational study.
The eligibility criteria for the study were the following:
1) a histopathologically-confirmed diagnosis of infiltrat-
ing ductal carcinoma; 2) stage II or III cancer according
Russo et al. BMC Cancer 2013, 13:56 Page 3 of 11
http://www.biomedcentral.com/1471-2407/13/56to the criteria of the International Union against Cancer
(UICC); 3) no upper GI disease and an ability to take in
soft solid foods orally; 4) Eastern Cooperative Oncology
Group performance status (PS) within the range of 0 to
1.5; 5) adequate function of major organs; 6) no other
active malignancy; and 7) provision of written informed
consent.
Pre-treatment clinical staging was based on liver echo-
graphy, computed tomography scans of the neck, chest,
and the upper and lower abdomen as continuous 5 mm-
thick slices and total body bone scans.
The exclusion criteria were: hypertension, diabetes
mellitus and other pathologies (e.g. systemic, endocrine,
collagen-related diseases). Subjects had not taken anti-
biotics, probiotics, vitamins, minerals, non-steroidal
anti-inflammatory or prokinetic drugs, bismuth, anta-
cids, H2-receptor antagonists, omeprazole, sucralfate or
misoprostol in the 4 weeks prior to the study and had
no previous history of gastric or duodenal ulcers or
major GI surgery. Patients needing PPIs and/or proki-
netic drugs to control their dyspeptic symptoms during
the adjuvant therapy were excluded from the study at
the time of analysis.
Adjuvant chemotherapy regimen
After the surgical resection of the tumor and lymph nodes
(primary therapy), all of the enrolled patients received adju-
vant chemotherapy. The adjuvant regimen consisted of
epirubicin-based chemotherapy. Specifically, the chemo-
therapy regimen consisted of FEC60 (Fluorouracil 600 mg/
m2, Epirubicin 60 mg/m2 and Cyclophosphamide 600 mg/
m2 every 21 days for 6 cycles).
There was no significant difference in the background
of tumor status and systemic condition between patients
who received adjuvant chemotherapy. Supportive ther-
apy and prophylaxis against expected side-effects was
provided. All of the patients were pre-medicated with
intravenous ondansetron (4 mg), infused 1 hour prior to
the administration of the scheduled drugs. Hypersensitivity
reactions were prophylactically treated with intravenous
dexamethasone (8 mg), which was infused 1 h prior to the
administration of chemotherapy. Granulocyte-stimulating
factor (G-CSF) was used for febrile neutropenia when
deemed necessary.
The study was performed in accordance with the Helsinki
Declaration and all participants gave written informed con-
sent to participate before enrolment. The protocol was
approved by the local Scientific and Ethics Committees and
the study was registered at www.clinicaltrials.gov, registra-
tion number: NCT01382667.
Blood sampling
For biochemical determinations, blood samples were
collected in vacutainer tubes in the morning (at 08.00 h)after fasting from midnight and before the first cycle of
chemotherapy (day 0), as well as on days 3, 10, 14 and
21 after the beginning of treatment.
Symptom recording
During the first cycle of chemotherapy, the severity of
oral mucositis was evaluated using the Oral Mucositis
Assessment Scale (OMAS) on day 0 and day 14. The
OMAS provides an objective assessment of oral mucosi-
tis based on the assessment of the appearance and
extent of redness and ulceration in various areas of the
mouth. Primary indicators were the degrees of ulceration/
pseudomembrane and mucosal erythema measured in
specific sites in the mouth. Secondary indicators included
oral pain, swallowing, and the ability to eat as assessed by
the patient [19].
Patients were evaluated for their GI symptoms with
the Gastrointestinal Symptom Scoring Rate (GSRS)
[20] on day 0 and day 14. The GSRS utilizes a seven-
level Likert scale (1 to 7), depending on the intensity
and frequency of GI symptoms experienced during the
previous week. A higher score indicates more inconvenient
symptoms.
During the period of observation, a list of GI symptoms
was also recorded by the visual analog score (VAS) scale
using a 100 mm horizontal line. Patients were asked to
complete diaries in which they were to assess the intensity
of a list of GI symptoms. Diaries were completed on 5
scheduled days (days 0, 3, 10, 14 and 21). Symptom scores
concerned “fatigue”, “anorexia”, “nausea/vomiting”, “ab-
dominal pain/discomfort”, “reflux disease”, and “early
satiety/postprandial fullness”. In particular, with regards
to “diarrhea”, patients were also asked to complete a
questionnaire to assess the severity of diarrhea as well
as a history of anti-diarrheal therapy at baseline and
after 14 days of chemotherapy. The questionnaire incor-
porated eight questions to rate the severity of their
diarrhea (based upon the number of bowel movements,
cramping, incontinence, the impact on daily life, and
duration more than one day), and also included
questions to facilitate the categorization of the patient’s
diarrhea according to the National Cancer Institute,
Common Toxicity Criteria for Diarrhea [21].
Intestinal permeability test
For intestinal permeability assessment, a probe solution
containing 10 g lactulose and 5 g mannitol in 100 ml
water was made. After an overnight fast, each subject
provided a pre-test urine sample. Then they drank the
test solution and collected all urine samples in the
following 5 hours. Samples were stored at −20°C until
analysis.
The detection and measurement of two sugar probes,
La and Ma, in urine was performed by chromatographic
Table 1 Mean Visual Analog Scale (VAS) and National
Cancer Institute Common Toxicity Criteria for Diarrhea
scores and standard deviation on day 0 and day 14 of
FEC60 regimen in 10 breast cancer patients who
experienced diarrhea during the FEC60 cycle
Scale Day 0 Day 14 p
VAS (0–10) 1.6 ± 0.3 3.4 ± 0.5 0.014
NCIC (0–4) 1.2 ± 0.9 1.9 ± 0.8 0.005
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minor modification. Briefly, high-performance anion ex-
change chromatography coupled with pulsed ampero-
metric detection was performed on a Dionex Model
ICS-5000 with a gold working electrode and a 25 μl
peek sample loop (Dionex Corp., Sunnyvale, CA, USA).
Carbohydrate separation was carried out by a Carbopac
PA-10 pellicular anion-exchange resin connected to a
Carbopac PA-10 guard column at 30°C. Samples were
eluted with 50 mM NaOH at the flow-rate of 1 ml/min.
For each sample the percentage of ingested lactulose
(La%) and mannitol (Ma%) in urine was evaluated and
their ratio (La/Ma) was calculated. The intestinal per-
meability was evaluated on the day before the beginning
of treatment (day 0) and on day 14 of chemotherapy
administration. In a subgroup of patients (8 pts) the
intestinal permeability was also evaluated on day 21.
Zonulin, EGF, Ghrelin and GLP-2 evaluation
Serum levels of zonulin and EGF were assayed using the
ELISA kits (Immunodiagnostik, Bensheim, Germany
and Boster Biological Technology, Fremont, USA, re-
spectively). The serum levels of ghrelin were assayed by
the Human Ghrelin EIA kit (Ray Biotech Inc, Norcross,
GA, USA).
For GLP-2 evaluation after overnight fasting, blood
samples were collected in ice-chilled tubes containing
500KIU/ml of aprotinin (100,000 KIU-MP Biomedicals,
LLC, Ohio, USA) and 1 mg EDTA/ml blood. The sam-
ples were centrifuged at 1600 × g for 15 min at 4°C and
the separated plasma was stored at −80°C until assayed.
The plasma was acidified with 1% trifluoroacetic acid
(TFA, HPLC grade) and then centrifuged at 3000 × g for
20 minutes at 4°C. The supernatant was loaded onto the
pre-treated C18 column (200 mg, Sep-columns, Peninsula
Laboratories Inc., Belmont, California, USA). The eluent
was evaporated to dryness using a centrifugal concen-
trator and then lyophilized. The plasma levels of GLP-2
were measured by EIA using a commercial kit (Phoenix
Pharmaceuticals, Burlingame, USA).
Peptide profiles in chemotherapy patients were evalu-
ated the day before the beginning of treatment (day 0)
and at each scheduled visit on days 3, 10, 14 and 21 of
the treatment.
Statistical analysis
Data were expressed as M±SEM or median values and
the range where reported. The rate of severity of diar-
rhea according to VAS scores was calculated to discrim-
inate between patients reporting chemotherapy-induced
diarrhea (VAS score > 0) and negative patients (VAS
score = 0).
In order to evaluate the release of peptides during
the time of observation, the area under the curve withrespect to ground (AUCg) was calculated. The AUCg
allows researchers to assess if any change occurred
over time, and is indicated in the case of a profile in
which data at a given point is lower than the basal
value. The area under the curve was calculated using
the trapezoid formula described by Pruessner et al. [23].
Parametric and non-parametric tests were applied
when appropriate. The relationship between parameters
was investigated by Spearman correlation analysis.
Statistical significance was set at p<0.05. The software
package used for the statistical analysis was StataCorp
2005 (Stata Statistical Software: Release 9, College
Station, TX, USA).Results
Patient characteristics
At the start of the study, the patients had a body mass
index (BMI) of 27.6±5.5. When evaluated on day 0,
none of the patients complained of oral mucositis
(total score = 0.014±0.012) or dyspeptic symptoms
(total score = 24.7±0.94) as evaluated by OMAS and
GSRS, respectively. Values are expressed as M±SEM.
Clinically, 40% of patients were at Stage II and 60%
were at Stage III. The applied chemotherapeutic
regimen for all of the patients was FEC60.Recurrence of oral mucositis and gastrointestinal
symptoms
At day 14 of the first FEC60 cycle, none of the patients
complained of oral mucositis and the OMAS score was
quite similar to day 0 (day 14 = 0.017±0.061). With
regards to GI symptoms, the GSRS in the whole group
was higher on day 14 of chemotherapy compared to
the baseline (total scores = 29.86±1.27 and 24.7±0.94,
respectively, p=0.02; Paired t-test).
According to VAS and NCI Criteria, 10 patients (29%)
(age = 57.6±3.99 yr.) suffered from diarrhea (Table 1),
but none of them required a reduction of their chemo-
therapy dose. This group of patients (chemotherapy-
induced diarrhea positive, CTD(+)) was considered for
further evaluation in comparison to patients in the
study who did not complain of this symptom (chemo-
therapy-induced diarrhea negative, CTD(−)). Data are
expressed as M±SEM.
Figure 1 Intestinal permeability after 14 days of FEC60.
Decreased intestinal permeability after 14 days of FEC60. Small
intestinal permeability was probed by measuring the urinary
cumulative 5-hour amount of lactulose (Lactulose% = percentage of
ingested lactulose), mannitol (Mannitol% = percentage of ingested
mannitol) and the Lactulose to Mannitol ratio. Data are reported as
medians and the range and analyzed with Wilcoxon matched-pairs
signed rank test.
Russo et al. BMC Cancer 2013, 13:56 Page 5 of 11
http://www.biomedcentral.com/1471-2407/13/56Intestinal permeability tests
As for small intestine permeability, La% was signifi-
cantly (p = 0.001) increased 14 days after the beginning
of treatment (day 14 = 0.067%; 0.005-0.82) compared
to that found at baseline (day 0 = 0.034%; 0.005-0.36)
(Figure 1, panel A). In contrast, Ma% was significantly
(p = 0.0002) reduced after two weeks of chemotherapy
(day 14: 0.41%; 0.005-4.20) compared to baseline (day
0 = 1.33%; 0.03-8.03) (Figure 1, panel B). As a result, the
La/Ma ratio was significantly (p = 0.0005) increased
after two weeks of chemotherapy (day 14 = 0.21; 0.06-
11.43) compared to baseline (day 0 = 0.03; 0.01-2.13)
(Figure 1, panel C). Data were analyzed by Wilcoxon
matched pair signed rank test and expressed as median
and the range.
In the group of patients (n = 8) in which the IP test
was also performed on day 21 at the end of the first
cycle of the FEC60 regimen, the La% and Ma% values
were essentially equal to those recorded on day 14 (data
not shown).
Interestingly, the intestinal barrier function, as measured
by urinary recovery of the two sugars, was found to be
different in CTD(+) patients from that in CTD(−) ones
(Figure 2).
At day 0, La% was lower in CTD(+) patients than
CTD(−) ones, even without statistical significance
(0.025%; 0.005-0.21 vs. 0.041%; 0.007-0.36). After 14 days
of treatment, La% increased significantly and by almost
three-fold (272%) in CTD(+) patients (p = 0.02) and
65% in CTD(−) ones (p = 0.03) as well (0.093%; 0.005-
0.33 vs. 0.068%; 0.007-0.82). However, at day 14 the dif-
ferences between the two groups were not significant
(Figure 2, panel A).
Also the Ma% recorded on day 0 was lower in CTD(+)
patients than CTD(−) patients, without reaching statistical
significance (0.865%; 0.033-2.30 vs. 1.43%; 0.038-8.03).
On day 14, Ma% in CTD(+) patients dramatically
and significantly decreased by 76.3% in comparison to
baseline values (p = 0.05), whereas in CTD(−) patients
the decrease was equal to 36% (p = 0.01) (0.205%;
0.0055-0.93 vs. 0.910%; 0.007-4.20). The difference in
the percentage of urinary recovery of mannitol between
CTD(+) and CTD(−) patients at day 14 was statistically
significant (p=0.01) (Figure 2, panel B).
With regards to the La/Ma ratio, before the start of
treatment on day 0, there was no significant difference
between the two groups (0.02; 0.01-0.75 vs. 0.03; 0.01-
2.13). After two weeks of treatment, the La/Ma ratio
increased dramatically and significantly by several-fold
in both CTD(+) patients (p = 0.014) and CTD(−) ones
(p = 0.004). Importantly, the La/Ma ratio of CTD(+)
patients was significantly higher (p = 0.001) than that
recorded in CTD(−) group (0.62; 0.11-11.43 vs. 0.10;
0.02-1.6) (Figure 2, panel C).
Figure 2 Intestinal permeability in patients with or without
chemotherapy induced diarrhea. Intestinal permeability in
patients who suffered from chemotherapy induced diarrhea, CTD(+),
and those who did not, CTD(−). Small intestinal permeability was
probed by measuring the urinary cumulative 5-hour amount of
lactulose (Lactulose% = percentage of ingested lactulose), mannitol
(Mannitol%) and the Lactulose to Mannitol ratio. Data are reported
as medians and the range and analyzed with Wilcoxon matched-
pairs signed rank test.
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differences within the groups and the Mann Whitney
test for differences between the groups, and results were
expressed as median and the range.
Gastrointestinal peptides
Figure 3 panel A shows the serial changes in total zonulin
concentration. The median serum total zonulin levels did
not change significantly compared to baseline during the
FEC60 cycle (day 0 = 28.9; 4.61-100.9 ng/ml; day 3 = 29.0;
0.89-100 ng/ml, day 10 = 33.0; 2.0-102 ng/ml; day 14 =
31.70; 6.7-104 ng/ml; day 21 = 32.44; 0.74-104 ng/ml).
The circulating levels of GLP-2 (Figure 3, panel B)
decreased significantly during the chemotherapy regi-
men (p = 0.0044). GLP-2 levels on day 14 (0.02; 0.001-
0.45 ng/ml) were significantly lower (p<0.05) than
those recorded on day 0 (0.025; 0.003-0.704 ng/ml)
and day 3 (0.025; 0.003-0.73 ng/ml), but not than levels
recorded on day 10 (0.024; 0.003-0.45 ng/ml) and day
21 (0.024; 0.003-0.80 ng/ml).
The EGF concentrations are shown in Figure 3, panel
C. A significant decrease during the FEC60 cycle
occurred (p = 0.004). EGF values on day 10 (0.347; 0.03-
2.94 ng/ml) were significantly lower (p<0.05) than those
recorded on day 0 (0.90; 0.03-3.88 ng/ml), but not than
levels recorded on day 3 (0.615; 0.03-3.17 ng/ml), day
14 (0.45; 0.025-3.45 ng/ml), and day 21 (0.69; 0.025-
3.61 ng/ml).
With regards to ghrelin (Figure 3, panel D), the total
concentration at day 3 (28.06; 14.26-53.0 ng/ml) increased
significantly (p<0.05) by 14.6% and 17.6% compared to
levels recorded at day 0 (21.38; 12.83-49.12 ng/ml) and
after completion of chemotherapy on day 21 (18.97;
13.48-58.34 ng/ml), respectively. In contrast, there were
no significant differences between day 3 and day 10
(20.16; 15.01-60.89 ng/ml) and day 14 (21.38; 12.83-
58.34 ng/ml). Data are expressed as median and the range
and analyzed with Friedman test and Dunn’s Multiple
Comparison Test. No correlation between intestinal
permeability and GI peptides was found.
The gut peptide profile of CTD(+) patients was also
analyzed in comparison to that of CTD(−) ones. Zonulin
and ghrelin levels did not change significantly compared
to starting values in both groups (Figure 4, panel A and
D). With regards to GLP-2 and EGF circulating concen-
trations, the gut peptide profile of CTD(+) patients was
found to be different from that of CTD(−) ones (Figure 4,
panel B and C). In CTD(+), but not in CTD(−) patients,
GLP-2 levels on day 14 (0.011; 0.001-0.050 ng/ml) were
significantly lower (p<0.05) than those recorded on day 0
(0.021; 0.008-0.07 ng/ml). Similarly, EGF values on day 10
(0.373; 0.03-1.13 ng/ml) were significantly lower (p<0.05)
than those recorded on day 0 (1.348; 0.098-2.313 ng/ml).
Data are expressed as the median and range and were
Figure 3 Basal plasma values of gut hormones during FEC60 protocol. Basal plasma values of gut hormones at baseline (day 0) and during
the scheduled days (day 3, day 10, day 14, day 21). Values not showing a common letter differ significantly. Data are reported as median and the
range and analyzed with Friedman test and Dunn’s Multiple Comparison Test.
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In order to calculate the differences of the total re-
lease of these peptides during the FEC60 cycle, the
AUCg values of zonulin, GLP-2, ghrelin and EGF were
calculated. The AUCg of zonulin were similar in the
two groups (621.7; 225.5-2148 vs. 662; 105.9-1647)
whereas the GLP-2 levels were significantly (p = 0.04)
lower in the CTD(+) group than in the CTD(−) one
(0.33; 0.09-0.85 vs. 0.66; 0.13-12.45). The AUCg values
of EGF were not significantly different in the two
groups (16.59; 1.33-25.69 vs. 15.57; 0.74-68.65). By
contrast, the AUCg values of ghrelin were significantly
higher (p = 0.0427) in the CTD(+) group compared to
those in the CTD(−) one (588.3; 275.8-1098 vs. 410.3;
152.8-985.4). Data were analyzed by the Mann Whitney
test and expressed as median and the range.
Finally, in the CTD(+) group a negative and signifi-
cant correlation between the La/Ma ratio and the
circulating levels of GLP-2 recorded on day 14 was
found (r = −0.854, p = 0.0029, Spearman correlation
coefficient) (Figure 5).
Discussion
Cytotoxic drugs may induce mucosal modifications
leading to an increased contact between luminal fluid
and the cryptal epithelium. Our study reports a signi-
ficant change of intestinal permeability mirrored by a
significant raise of the La/Ma ratio recorded on day 14,and persisting until the end of the first cycle of chemo-
therapy. It appeared to be determined by a concomitant
increase in La% and decrease in Ma%. In this condition,
the passive transport of monosaccharides decreases,
while more disaccharides may cross the mucosa through
large pores [8]. This finding is in line with data showing
an involvement of cytotoxic drugs in the processes
regulating macromolecular passage through both para-
cellular and transcellular pathways.
To the best of our knowledge, this is the first attempt
to evaluate the existence of effects due to the FEC60
regimen on the intestinal barrier functioning and the re-
lease of peptides involved in the regulation of intestinal
permeability in cancer patients. FEC60, based on 5FU,
cyclophosphamide, and epirubicin is now the most com-
monly used FEC regimen as adjuvant treatment for
breast cancer patients. It is active and well tolerated but,
apart from leukopenia, common adverse events include
the increase in liver enzymes and a series of GI symp-
toms, such as nausea, vomiting and diarrhea [24]. In this
framework, the breast cancer patients involved in this
study had a relatively fair systemic status and stable
tumor progression. Furthermore, they did not suffer
from a direct involvement of the GI tract, and so they
represented an appropriate cohort for investigating the
above issues.
Data in the literature suggest that, where permeability
is increased, a common pathophysiological event is the
up-regulation of zonulin secretion from a lamina propria
Figure 4 Gut hormone profiles in patients with or without chemotherapy induced diarrhea. Basal plasma values of gut hormones at
baseline (day 0) and during the scheduled days (day 3, day 10, day 14, day 21) in patients who suffered from chemotherapy induced diarrhea,
CTD(+), and those who did not, CTD(−). Values not showing a common letter differ significantly. Data are reported as median and the range and
analyzed with Friedman test and Dunn’s Multiple Comparison Test.
GLP-2





















Figure 5 Correlation between Lactulose to Mannitol ratio and
GLP-2. Negative and significant correlation (r = −0.854, p = 0.0029
Spearman correlation coefficient) between intestinal permeability as
expressed by Lactulose to Mannitol ratio and the circulating levels of
GLP-2 recorded on day 14 in the group of patients who suffered
from chemotherapy induced diarrhea, CTD(+).
Russo et al. BMC Cancer 2013, 13:56 Page 8 of 11
http://www.biomedcentral.com/1471-2407/13/56source into the lumen with an inappropriate activation
of this pathway. As a consequence, the end result is
increased paracellular permeability [25]. However, in
the patients studied here, zonulin levels were not
affected by chemotherapy, which is a finding that is not
completely surprising since previous studies performed
on laboratory animals have already demonstrated that
chemotherapy is able to increase IP without affecting
the expression or the circulating levels of zonulin [26].
Available reports strongly support a key role for en-
dogenous peptides in promoting an adequate trophic
status in intestinal mucosa to help maintain its barrier
function [27]. In this connection, different GI peptides
have been considered therapeutic tools in gut diseases
and some of them, especially those that have a trophic
action on the intestinal mucosa, like GLP-2 and EGF,
have been identified for their potential clinical use [28].
However, there is still little information about circulating
levels of these peptides during chemotherapy in humans.
Present data show that the circulating levels of GLP-2
decreased significantly during chemotherapy, reaching
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This happened in conjunction with the significant increase
of intestinal permeability. This datum is in accordance
with studies showing that GLP-2 enhances intestinal
epithelial barrier function by affecting both paracellular
and transcellular pathways in mice [29]. Also, EGF was
found to decrease significantly during chemotherapy,
reaching the lowest circulating concentration at day 10.
This lowering corresponds with the reported peak in
the occurrence of mucositis [8]. EGF is considered to be
an effective mitogen for intestinal mucosa [16]. Add-
itionally, treatment with EGF before and after irradi-
ation has been proven to limit the manifestations of
mucositis [16]. Our data for GLP-2 and EGF seem in
agreement with the assumption of a combined action of
these two peptides. As a matter of fact, the biology of
GLP-2 in the gut overlaps to a considerable extent with
the actions of ErbB ligands (including EGF, along with
other peptides such as betacellulin, TGF-alpha, amphir-
egulin) as well as their receptors [30]. Both EGF and
GLP-2 stimulate cell proliferation [31,32], enhance mu-
cosal adaptation following small bowel resection [16,33]
and accelerate recovery of epithelial integrity following
radiation-induced injury [34,35]. Besides, concomitant
administration of GLP-2 and EGF has additive effects
increasing small intestinal weight, cellular proliferation,
and morphometric measurements of villus and crypt
area [36].
A differing behavior was observed for ghrelin that
rapidly rouse on day 3 of treatment and rapidly lowered
to normal values on day 10. This peptide represents the
natural endogenous ligand for GH secretagogue recep-
tors (GHS) originally isolated from rat and human
stomach [37], and subsequently identified in various
tissues, including the small bowel [38]. Diseases of the
intestines, including inflammatory processes, can mod-
ify ghrelin levels [39,40]. It has been suggested that the
inhibition of ghrelin secretion during inflammatory pro-
cesses might potentiate the ongoing inflammatory insult
[39]. The rapid increase in ghrelin levels observed on
day 3 may be concomitant with the initial phase of the
mucositis process in the gut [1], thus representing an
acute response against the damage induced by cytotoxic
drugs. Overall, these data led to the hypothesis of a
strong implication for GI peptides in the occurrence of
intestinal barrier dysfunction during the administration
of chemotherapeutic regimens to breast cancer patients.
Of note, the changes in circulating gut peptides and
the alterations of intestinal permeability appeared to be
associated with clinical manifestations of GI toxicity, the
global symptom profile being affected by the first
chemotherapy cycle, and 10 out 37 patients (27%)
suffered from diarrhea. Diarrhea is one of the most
common chemotherapy side-effects [41] and differentmechanisms may be involved in its pathogenesis
reflecting an imbalance between the secretory activity
of cryptal epithelial cells and absorption by the villar
epithelium [8].
Firstly, a dramatic and significant increase of intestinal
permeability in CTD(+) patients but not in CTD(−)
ones occurred on day 14. Secondly, CTD(+) patients
exhibited a lower GLP-2 profile compared to CTD(−)
ones, reaching the lowest level on day 14. On the con-
trary, ghrelin levels were higher in CTD(+) patients than
CTD(−) ones, reaching the peak on day 3. Lastly, a sig-
nificant and negative correlation between the lactulose
to mannitol ratio and GLP-2 levels recorded on day 14
was found in CTD(+) patients. Taken as a whole, these
results agree with other data in the literature showing
an involvement of GLP-2 and ghrelin in the onset of
diarrhea following alterations of the intestinal barrier
function.
It has been reported that mice with a disruption of the
prohormone convertase-1 gene exhibited marked reduc-
tions in the intestinal levels of GLP-2, reduced somatic
growth, and diarrhea, suggesting that GLP-2 action may
contribute to regulation of murine intestinal function
in vivo [42]. Besides, a therapeutic role for GLP-2 in the
management of diarrhea induced by cytotoxic drugs has
been hypothesized. Physiologically, GLP-2 delays gastric
emptying, perhaps by inhibiting centrally induced antral
motility [43], thereby acting as one of the mediators of
the so-called ileal brake. The global combination of
intestinetrophic effects, functional improvement, and an
enterogastrone effect have made GLP-2 promising as an
agent also for the treatment of cancer patients suffering
from diarrhea, and the findings of this study seem to
further support this novel therapeutic indication [44].
As far as ghrelin is concerned, previous papers have
demonstrated that patients with GI diseases affecting
intestinal barrier functions, such as celiac disease,
showed high hormone levels compared to healthy con-
trols. In addition, ghrelin levels correlated significantly
with the degree of the severity of intestinal mucosal
lesions. Present findings substantiate the hypothesis that
there is an inter-play of hormonal, metabolic, and nutri-
tional factors that could also influence ghrelin secretion
under pathophysiological circumstances [42].
Conclusions
It could be supposed that in patients with extra GI neo-
plasms, such as breast cancer, the FEC60 protocol induces
alterations in the intestinal permeability associated with
modifications in the levels of those hormones regulating
the growth and physiology of intestinal membranes (such
as GLP-2, ghrelin and, to a less extent, EGF). In the group
of patients with diarrhea, a different GI peptide profile
and increased intestinal permeability were found.
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present data and to investigate the potentially different
susceptibility of patients undergoing chemotherapy
who have diarrhea due to possible intestinal luminal
conditions (e.g. peculiar microbiota and/or possible
shifts in the intestinal microbial populations).
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